Researches reported that PARP3 is a driver gene to TGFβ-induced epithelial-to-mesenchymal transition and its inhibitors sensitize breast cancer cells to vinorelbine which was used in the treatment of metastatic breast cancer (Beck et al., 2019; Sharif-Askari et al., 2018). The gene discussed is PARP3; the disease is breast cancer.